Carcinomas News and Research

RSS

Scientists shed light on roles of transcription factors, TP63 and SOX2, in squamous cell carcinoma

Squamous cell carcinomas are aggressive malignancies arising from squamous epithelium of various organs, such as esophagus, head and neck, lung and skin. Previous studies demonstrated that two master transcription factors, TP63 and SOX2, effect genomic activation in SCCs.

15 Oct 2018

Two major studies on canine cancers may provide clues on human cancers

Two studies into deadly cancers in dogs are now underway, offered through the newly formed Clinical Trials Office at Cummings Veterinary Medical Center at Tufts University. Dogs with spontaneous osteosarcoma, as well as dogs with mast cell tumors and solid tumors, may be eligible for enrollment.

12 Oct 2018

Study identifies tumor cell population responsible for resistance to therapy and cancer relapse

Resistance to therapy is a major problem in cancer patients as the cells that resist to therapy is at the root of tumor relapse and is associated with high morbidity and mortality.

9 Oct 2018

Not all P53 mutations cause skin cancer

Today, scientists have explained for the first time why not all UV-induced, P53 mutated skin cells develop into cancer.

27 Sep 2018

Researchers use CRISPR screen to reveal new targets in squamous cell carcinomas

A little p63 goes a long way in embryonic development - and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs.

18 Sep 2018

Cellular environment affects type of tumor development

Liver cancer is the second leading cause of cancer death worldwide. Two different forms of primary liver cancer cover the majority of cases: About 10 to 20 percent of those affected develop a bile duct carcinoma within the liver (intrahepatic cholangiocellular carcinoma; ICC), the far higher proportion of liver cancers are hepatocellular carcinomas.

12 Sep 2018

New nuclear medicine imaging method could help diagnose widespread tumors

A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.

6 Sep 2018

Researchers identify enzyme that plays vital role in sexual development of fungi

Biologists at Ruhr-Universität Bochum and Georg-August-Universität Göttingen have gained new insights into specific enzymes that effect the specialization of fungal cells.

5 Sep 2018

Five microRNAs predict course, recurrence of HPV-negative head and neck cancer

A new method predicts the course of HPV-negative head and neck cancer after radiation chemotherapy.

4 Sep 2018

Immune-related enzymes cause aggressive skin cancer in patients with Butterfly Syndrome

Patients with a rare skin disease, commonly called Butterfly Syndrome, that causes chronic blistering and extensive scarring also develop an aggressive and fatal form of cancer early in life.

28 Aug 2018

Blood biomarker could help predict kidney cancer up to five years prior to diagnosis

Every year, more than 330,000 people are diagnosed with kidney cancer worldwide. More than 80 percent of those new cases are renal cell carcinomas.

17 Aug 2018

Scientists unravel the mystery behind ovarian cancer with high-grade serous carcinoma

More than two-thirds of women with ovarian cancer have high-grade serous carcinoma. Up to 90 percent of HGSCs are not detected until they are beyond the ovaries or fallopian tubes, at which point it may not be possible to fully remove the tumor.

14 Aug 2018

Study identifies distinct genetic mutations in appendix cancer that may impact treatment

The rarity of appendix cancer, accounting for less than 1 percent of tumors that originate in the gastrointestinal tract, and the lack of scientific data for this disease means that current treatment guidelines recommend applying therapies to people with appendix cancer that are intended for those with colon cancer.

9 Aug 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Molecules formed when the body metabolizes omega-3 fatty acids may inhibit cancer

A class of molecules formed when the body metabolizes omega-3 fatty acids could inhibit cancer's growth and spread, University of Illinois researchers report in a new study in mice.

16 Jul 2018

Researchers discover way to reverse drug resistance in some skin and mouth cancers

University of Queensland researchers have discovered how to reverse drug resistance in skin and mouth squamous cell carcinomas.

29 Jun 2018

UC Riverside researcher receives grants to advance cancer, ALS research

Maurizio Pellecchia, who holds the Daniel Hays Chair in Cancer Research at the University of California, Riverside, has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

21 Jun 2018